• 1
    Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575581.
  • 2
    Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrohy due to chronic arterial hypertension in humans. J Hypertens. 1998;16:10311041.
  • 3
    Schwartzkopff B, Brehm M, Mundhenke M, et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000;36:220225.
  • 4
    Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:13881393.
  • 5
    Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:17291735.
  • 6
    Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568575.
  • 7
    Varo N, Etayo JC, Zalba G, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 1999;17:107114.
  • 8
    Varo N, Iraburu MJ, Varela M, et al. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35:11971202.
  • 9
    Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res. 1999;42:2744.
  • 10
    López B, González A, Díez J. Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens. 2004;13:197204.
  • 11
    Amanuma S, Sekiguchi M, Ogasawara S, et al. Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J. 1994;70(suppl 1):S67S71.
  • 12
    Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400405.
  • 13
    López B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286291.
  • 14
    Díez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:25122517.
  • 15
    González A, López B, Querejeta R, et al. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol. 2002;34:15851593.
  • 16
    Díez J. Profibrotic effects of angiotensin II in the heart: a matter of mediators. Hypertension. 2004;43:11641165.
  • 17
    Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865879.
  • 18
    Brilla CG, Matsubara LS, Weber KT. Antifibrotic effect of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A16A.
  • 19
    Kuster GM, Kotlyar E, Rude MK, et al. Mineralcorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420427.
  • 20
    Rosenkranz S, Flesch M, Amann K, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 2002;283:H1253H1262.
  • 21
    Laviades C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension. 2000;36:517522.
  • 22
    Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 2002;39:258263.
  • 23
    Sappino AP, Schürch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 1990;63:144161.
  • 24
    Vracko R, Thorning D. Contractile cells in rat myocardial scar tissue. Lab Invest. 1991;65:214227.
  • 25
    Katwa LC, Campbell SE, Tyagi SC, et al. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol. 1997;29:13751386.
  • 26
    Jacob HJ, Lindpaintner K, Lincoln SE, et al. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell. 1991;67:213224.
  • 27
    Challah M, Villard E, Phillippe M, et al. Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Arterioscler Thromb Vasc Biol. 1998;18:235243.
  • 28
    Ocaranza MP, Diaz-Araya G, Carreno JE, et al. Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol Heart Circ Physiol. 2004;286:H498H506.
  • 29
    Díez J, Laviades C, Orbe J, et al. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens. 2003;21:20852092.
  • 30
    Yu HC, Burrell LM, Black MJ, et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation. 1998;98:26212628.
  • 31
    Ahn J, Varagic J, Slama M, et al. Cardiac structural and functional responses to salt loading in SHR. Am J Physiol Heart Circ Physiol. 2004;287:H767H772.
  • 32
    Varagic J, Frohlich ED, Díez J, et al. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. Am J Physiol Heart Circ Physiol. 2006;290:H1503H1509.
  • 33
    Aurigemma GP, Gaasch WH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology. 1995;86:310317.
  • 34
    Villari B, Campbell SE, Schneider J, et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J. 1995;16:14101419.
  • 35
    Deschepper CF, Llamas B. Hypertensive cardiac remodelling in males and females. From the bench to the bedside. Hypertension. 2007;49:401407.
  • 36
    Asbun J, Villarreal FJ. The patogénesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;47:693700.
  • 37
    Ahmed Q, Chung-Park M, Tomashefski JF Jr. Cardiopulmonary pathology in patients with sleep apnea/obesity hypoventilation syndrome. Hum Pathol. 1997;28:264269.
  • 38
    Amann K, Tyralla K. cardiovascular changes in chronic renal failure-pathogenesis and therapy. Clin Nephrol. 2002;58(suppl 1):S62S72.
  • 39
    Peterson MC. Circulating transforming growth factor β-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit. 2005;11:RA229RA232.
  • 40
    Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:12631268.
  • 41
    López B, González A, Querejeta R, et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:8996.
  • 42
    González A, López B, Díez J. New directions in the assessment and treatment of hypertensive heart disease. Curr Opin Nephrol Hypertens. 2005;14:428434.